Toxicity and toxicokinetics of metformin in rats

Toxicology and Applied Pharmacology

Volumn 243, Issue 3, 2010, Pages 340-347

  Quaile, Michael P ^a   Melich, David H ^a   Jordan, Holly L ^a   Nold, James B ^a   Chism, Jack P ^a   Polli, Joseph W ^a   Smith, Glenn A ^a   Rhodes, Melissa C ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Diabetes; Metformin; Toxicity; Toxicokinetics

Indexed keywords

3 HYDROXYBUTYRIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BICARBONATE; CALCIUM; CHLORIDE; CREATININE; GLUCOSE; LACTIC ACID; METFORMIN; PHOSPHORUS; POTASSIUM; SODIUM; TRIACYLGLYCEROL; UREA;

ADRENAL GLAND; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CHLORIDE URINE LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; FOOD INTAKE; GLUCOSE URINE LEVEL; HEART WEIGHT; HISTOPATHOLOGY; INFLAMMATION; KIDNEY MASS; LACTATE BLOOD LEVEL; LIVER WEIGHT; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC ACIDOSIS; MORTALITY; NONHUMAN; ORGAN WEIGHT; PAROTID GLAND; POTASSIUM EXCRETION; RAT; RELATIVE DENSITY; REPEATED DRUG DOSE; SEX DIFFERENCE; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE NECROSIS; TOXICOKINETICS; TOXICOLOGY; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE PH; WEIGHT REDUCTION;

ANIMALS; AREA UNDER CURVE; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; FEMALE; HYPOGLYCEMIC AGENTS; LIVER FUNCTION TESTS; MALE; MASS SPECTROMETRY; METFORMIN; OPHTHALMOSCOPY; RATS; SEX CHARACTERISTICS; SURVIVAL ANALYSIS; URINALYSIS;

RATTUS;

EID: 77049124491     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.11.026     Document Type: Article

References (15)

1. Bailey C.J. Biguanides and NIDDM. Diabetes Care 15 (1992) 755-772
2. Bailey C.J., and Turner R.C. Metformin. N. Engl. J. Med. 334 (1996) 574-579
3. Chiasson J.L., and Naditch L. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 24 (2001) 989-994
4. Dunn C.J., and Peters D.H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49 (1995) 721-749
5. Goldstein B.J., Feinglos M.N., Lunceford J.K., Johnson J., and Williams-Herman D.E. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30 (2007) 1979-1987
6. Guntupalli J., Eby B., and Lau K. Mechanism for the phosphaturia of NH4Cl: dependence on acidemia but not on diet PO4 or PTH. Am. J. Physiol. 242 (1982) F552-F560
7. Hoffmann J., and Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am. J. Med. 103 (1997) 483-490
8. Holman R.R., Cull C.A., and Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 22 (1999) 960-964
9. Hundal R.S., Krssak M., Dufour S., Laurent D., Lebon V., Chandramouli V., Inzucchi S.E., Schumann W.C., Petersen K.F., Landau B.R., and Shulman G.I. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49 (2000) 2063-2069
10. K Belton S.T. Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Postgrad. Med. J. 75 (1999) 509-510
11. Nowik M., Picard N., Stange G., Capuano P., Tenenhouse H.S., Biber J., Murer H., and Wagner C.A. Renal phosphaturia during metabolic acidosis revisited: molecular mechanisms for decreased renal phosphate reabsorption. Pflugers Arch. 457 (2008) 539-549
12. Ou H.Y., Cheng J.T., Yu E.H., and Wu T.J. Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects. Horm. Metab. Res. 38 (2006) 106-111
13. Schweizer A., Couturier A., Foley J.E., and Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet. Med. 24 (2007) 955-961
14. Timmins P., Donahue S., Meeker J., and Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin. Pharmacokinet. 44 (2005) 721-729
15. Tucker G.T., Casey C., Phillips P.J., Connor H., Ward J.D., and Woods H.F. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol. 12 (1981) 235-246